CStone Pharmaceuticals Submits EMA Application for Sugemalimab to Treat Unresectable Stage III NSCLC

CStone Pharmaceuticals, a biopharmaceutical company dedicated to developing innovative cancer therapies, announced the submission of a Type II variati...

March 24, 2025 | Monday | News
Terumo Neuro Celebrates 15th Anniversary of WEB™ Aneurysm Embolization System, Revolutionizing Aneurysm Treatment

Terumo Neuro, a global leader in neurovascular innovation and a wholly-owned subsidiary of Terumo Corporation, proudly celebrates the 15th anniversary of t...

March 24, 2025 | Monday | News
Novartis Wins FDA Approval for Fabhalta®, First Oral Therapy for C3G

Novartis announced that oral Fabhalta® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with ...

March 24, 2025 | Monday | News
Bristol Myers Squibb Secures European Approval for Breyanzi® in Relapsed or Refractory Follicular Lymphoma

 Bristol Myers Squibb  announced that the European Commission (EC) has granted approval to Breyanzi® (lisocabtagene maraleucel; lis...

March 18, 2025 | Tuesday | News
Roche Opens Genentech Innovation Center in Boston, Expands Harvard R&D and AI Collaboration

Roche  announced  the launch of the Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus in Allston which will ...

March 10, 2025 | Monday | News
Belén Garijo Leads Merck Back to Profitable Growth, Delivering Strong 2024 Performance

  Key Financial Highlights: Full-year net sales increased to €21.2 billion (organically: +2.0%) EBITDA pre rose to €6.1 billion (orga...

March 06, 2025 | Thursday | Company results
FDA Accepts Roche’s sBLA for Gazyva®/Gazyvaro® (Obinutuzumab) as a Treatment for Lupus Nephritis

Roche announced  that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for...

March 06, 2025 | Thursday | News
Roche Reports Positive Phase III OUtMATCH Data, Strengthening Xolair® for Food Allergies

Roche announced new positive data from Stage 2 and Stage 3 of the National Institutes of Health (NIH)-sponsored phase III OUtMATCH study, which provide fur...

March 06, 2025 | Thursday | News
CordenPharma Commits >€1 Billion to Expand Peptide Manufacturing Across Europe and the US

  CordenPharma is making a record investment of >€1 billion over the next 3 years in building and / or expanding small, medium, and la...

March 05, 2025 | Wednesday | News
Enzene India Secures EU GMP Certification for Pune Facilities, Strengthening Global Biologics Manufacturing

Enzene, a pioneer in fully-connected continuous biologics manufacturing technology, today announced that its two facilities in Pune have received Europea...

March 05, 2025 | Wednesday | News
Celon Pharma Announces Positive Phase 2 Results for CPL’36 in Treating Levodopa-Induced Dyskinesia in Parkinson's Disease

Celon Pharma S.A.  announces robust and positive Phase 2 clinical trial results for its PDE10A inhibitor (CPL’36), a novel, oral, once-daily med...

March 05, 2025 | Wednesday | News
Axplora Expands ADC Manufacturing Leadership with New Payload Facility in France

Axplora, a global leader in API small molecule and ADC (antibody-drug conjugate) manufacturing, is strengthening its leading position in the commercial m...

March 04, 2025 | Tuesday | News
QIAGEN Sues bioMérieux in German Patent Court to Protect QuantiFERON Technology

QIAGEN files lawsuit against bioMérieux with German Unified Patent Court to protect key innovations in its QuantiFERON technology Qua...

March 03, 2025 | Monday | News
Medigene and EpimAb Partner to Advance Off-the-Shelf TCR-TCE Therapies for Cancer

Medigene AG and EpimAb Biotherapeutics, Inc. (EpimAb), announced that the companies have entered a strategic co-development agreement to research and dev...

February 27, 2025 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close